|
Tsen-Fang Tsai describes for SIIC the most significant aspects of his article describe para SIIC los aspectos relevantes de su artículo ADALIMUMAB IN PSORIASIS PATIENTS WHO FAILED ETANERCEPT The effect of adalimumab on psoriasis is less favorable after failing prior etanercept in reimbursed patients who also failed conventional therapy as well as phototherapy previously The article was published by El artículo fue publicado por
Principal institution where the research took place Institución principal de la investigación 臺大醫院皮膚科, Taipei, Taiwan, Taiwan  Authors' Report Crónica del Autor Bibliographic references Referencias bibliográficas Bhutani T, Koo J. Paradoxical worsening of psoriasis when switching from tanercept to adalimumab: a case series. J Dermatol Treat 22:75e8, 2011. Bombardieri S, Ruiz AA, Fardellone P, et al. Research in Active Rheumatoid arhritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNFantagonist therapy in clinical practice. Rheumatology 46:1191e9, 2007. Chiu HY, Huang PY, Jee SH, Hu CY, Chou CT, Chang YT, Hwang CY, Tsai TF. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol 166(2):288-97, 2012. Chiu HY, Wang TS, Cho YT, Tsai TF. Etanercept use for psoriasis in Taiwan: a case series study. Int J Dermatol 52(6):673-80, 2013. Lecluse LL, de Groot M, Bos JD, Spuls PI. Experience with biologics for psoriasis in daily practice: switching is worth a try. Br J Dermatol 161:948e51, 2009. Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol 23:1394e7, 2009. Migliore A, Bizzi E, Broccoli S, Laganà B. Indirect comparison of etanercept, nfliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator. Clin Rheumatol 31:133e7, 2012. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 57:269e75, 2007. Ryan C, Kirby B, Collins P, Rogers S. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis. Clin Exp Dermatol 34:784e8, 2009. Woolf RT, Smith CH, Robertson K, Barker JN. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study. Br J Dermatol 163:889e92, 2010. Other articles written by the author Tsen-Fang Tsai Otros artículos de Tsen-Fang Tsai 188. T.-F. Tsai, V. Ho, M. Song, P. Szapary, T. Kato, Y. Wasfi, S. Li, Y.K. Shen, C. Leonardi. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012 Nov; 167(5): 1145–1152. 176. Hsien-Yi Chiu, Pei-Ying Huang, Shiou-Hwa Jee, Chung-Yi Hu, Chung-Tei Chou, Yun-Ting Chang, Chian-Yaw Hwang,Tsen-Fang Tsai. Human leukocyte antigens polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol2012 Feb;166(2): 188-197. 174. Hsien-Yi Chiu, Ting-Shun Wang, Tsen-Fang Tsai. The effectiveness and safety of adalimumab in the treatment of non-reimbursed patients with mild-to-moderate psoriasis. J Eur Acad Dermatol Venereol2012 Aug;26(8):991-8. 168. Tsen-Fang Tsai, Ji-Chen Ho, Michael Song, Philippe Szapary, Cynthia Guzzo, Yuang-Kuang Shen, Shu Li, Kwang-Joong Kim, Tae-Yoon Kim, Jee-Ho Choi, Jai-Il Younon behalf of the PEARL Investigators. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011 Sep;63(3):154-163. 154. Hsien-Yi Chiu, Po-Ren Hsueh, Tsen-Fang Tsai*.Clinical experience of QuantiFERON®-TB Gold testing in psoriasis patients treated with tumour necrosis factor blockers in Taiwan.Br J Dermatol2011 Mar;164(3):553-9 150. Hsien Yi Chiu, Tsen-Fang Tsai*. Topical use of systemic drugs in dermatology: A comprehensive review. J Am Acad Dermatol 2011 Nov; 65( 5), 1048.e1-1048.e22 121. PH Huang, YH Liao, CC Wei, YH Tseng, JC Ho, TF Tsai*. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multi-centre pilot study. J Eur Acad Dermatovenereol 2008 Aug;22:923–930 114. Liao YH, Chiu HC, Tseng YS, Tsai TF*.Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007 Nov, 157(5): 1005–1012 52. Tsen-Fang Tsai, Chung-Yi Hu,Wei-Ling Tsai,Shwu-Huey Liaw, Bor-Luen Chiang, Pei-Jung Lin,Shiou-Hwa Jee. HLA-Cw6 Specificity and Polymorphic Residues are Associated with Susceptibility among Chinese Psoriatics in Taiwan. Arch Dermatol Res 2002;194:214-220 SIIC System of Assisted Editing (SSEA) / Sistema SIIC de Edición Asistida (SSEA)
The article is strictly related to the following sections of siicsalud El artículo se relaciona estrictamente con las siguientes secciones de siicsalud
Information about the full text Acerca del trabajo completo Safety and Effectiveness of Adalimumab in Patients With Moderate-to-Severe Psoriasis Who Had Inadequate Therapeutic Response to Prior Etanercept Author / Autor Tsen-Fang Tsai1, Ting-Shun Wang2 2 M.d., Department Of Dermatology, National Taiwan University Hospital, Staff Access to the original source Dermatologica Sinica Other data bases: / Otras bases de datos: http://http://www.derm-sinica.com/article/S1027-8117(12)00079-1/abstract siic DB: / siic DB: http://www.siicsalud.com/main/distriprinrel.php |
||||||||||||||||||||||||
Copyright siicsalud © 1997-2024 ISSN siicsalud: 1667-9008
